Related Experiment Video
Updated: Jun 5, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations
Chia-Chi Lin1, James Chih-Hsin Yang
1Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Abstract:
In recent years, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, which have promising activity and a favourable toxicity profile, have been used in the management of advanced non-small cell lung cancer (NSCLC). The knowledge that EGFR-activating mutations confer sensitivity to EGFR TKIs has led to the design and analysis of phase II and III studies of gefitinib or erlotinib treatment in various clinical scenarios. We review the important NSCLC clinical trials of the efficacy of EGFR TKIs in the context of EGFR-activating mutations. In all phase II single-arm studies or phase III randomized comparative studies, EGFR TKIs as monotherapy were superior to combination chemotherapy in terms of response rate and progression-free survival in patients with activating EGFR mutations. EGFR TKIs have contributed to the superior overall survival time in NSCLC patients with EGFR mutations compared with those patients without EGFR mutations. The results of these studies have led to a paradigm shift in the treatment of patients with advanced NSCLC. NSCLC with EGFR mutations constitutes a new entity requiring different personalized treatment strategies.
Insights
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) significantly improve outcomes for non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations, outperforming chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- Advanced non-small cell lung cancer (NSCLC) treatment has evolved with targeted therapies.
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show promise in NSCLC management.
- EGFR mutations are key predictors of TKI sensitivity.
Purpose of the Study:
- To review clinical trials evaluating EGFR TKIs in NSCLC patients with EGFR-activating mutations.
- To assess the efficacy of EGFR TKIs compared to chemotherapy.
- To highlight the impact of EGFR mutations on treatment strategies.
Main Methods:
- Review of phase II and III clinical trials.
- Analysis of studies involving gefitinib and erlotinib.
- Comparison of EGFR TKIs monotherapy versus combination chemotherapy.
Main Results:
- EGFR TKIs demonstrated superior response rates and progression-free survival compared to chemotherapy in patients with EGFR mutations.
- EGFR TKIs contributed to improved overall survival in patients with EGFR mutations.
- EGFR mutation status is a critical factor in NSCLC treatment outcomes.
Conclusions:
- EGFR TKIs represent a paradigm shift in advanced NSCLC treatment.
- NSCLC with EGFR mutations is a distinct entity requiring personalized therapy.
- Targeted therapy based on EGFR mutation status is crucial for effective NSCLC management.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...